[<i>Pingchuanning</i> Formula suppresses airway inflammation in a rat model of asthmatic cold syndrome by regulating the HMGB1/Beclin-1 axis-mediated autophagy].

PCN can effectively alleviate airway inflammation in rat models of asthmatic cold syndrome possibly by modulating the HMGB1/Beclin-1 signaling axis to suppress cell autophagy, thereby attenuating airway inflammatory damages.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2025-06-20
DOI
https://doi.org/10.12122/j.issn.1673-4254.2025.06.05
Primary Topic
Advanced Glycation End Products research
Type
article
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

[Pingchuanning Formula suppresses airway inflammation in a rat model of asthmatic cold syndrome by regulating the HMGB1/Beclin-1 axis-mediated autophagy].

Xinheng Wang, Weidong Ye, Xiaowei Shao, Qinjun Yang et al.
PubMed
Advanced Glycation End Products research
article

[Pingchuanning Formula suppresses airway inflammation in a rat model of asthmatic cold syndrome by regulating the HMGB1/Beclin-1 axis-mediated autophagy].

Xinheng Wang, Weidong Ye, Xiaowei Shao, Qinjun Yang, Jiabing Tong, Zegeng Li, Tongtong Li, Zhang Lu, Xiangming Fang
article en

Abstract

PCN can effectively alleviate airway inflammation in rat models of asthmatic cold syndrome possibly by modulating the HMGB1/Beclin-1 signaling axis to suppress cell autophagy, thereby attenuating airway inflammatory damages.

PubMedVol. 45(6)
Anhui University of Traditional Chinese Medicine (CN)
Advanced Glycation End Products research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.